These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11073167)

  • 21. Incidence of myeloproliferative neoplasms - trends by subgroup and age in a population-based study in Sweden.
    Hultcrantz M; Ravn Landtblom A; Andréasson B; Samuelsson J; Dickman PW; Kristinsson SY; Björkholm M; Andersson TM
    J Intern Med; 2020 Apr; 287(4):448-454. PubMed ID: 31927786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients.
    Cervantes F; Tassies D; Salgado C; Rovira M; Pereira A; Rozman C
    Acta Haematol; 1991; 85(3):124-7. PubMed ID: 2042444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myeloproliferative disorders in the department of Côte d'Or between 1980 and 1986.
    Heudes D; Carli PM; Bailly F; Milan C; Mugneret F; Petrella T
    Nouv Rev Fr Hematol (1978); 1989; 31(5):375-8. PubMed ID: 2587208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The incidence of JAK2 V617F mutation in bcr/abl-negative chronic myeloproliferative disorders: assessment by two different detection methods.
    Lucia E; Martino B; Mammi C; Vigna E; Mazzone C; Gentile M; Qualtieri G; Bisconte MG; Naccarato M; Gentile C; Laganà C; Romeo F; Neri A; Nobile F; Morabito F
    Leuk Lymphoma; 2008 Oct; 49(10):1907-15. PubMed ID: 18720212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thrombosis and risk factors in female patients with a rare acquired thrombophilia: chronic myeloproliferative disorder - polycythaemia vera and essential thrombocythaemia.
    Pósfai É; Marton I; Kiss-László Z; Kotosz B; Széll M; Borbényi Z
    Eur Rev Med Pharmacol Sci; 2014; 18(24):3810-8. PubMed ID: 25555871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leukemia and related disorders.
    Anderson RE
    Hum Pathol; 1971 Dec; 2(4):505-14. PubMed ID: 5286449
    [No Abstract]   [Full Text] [Related]  

  • 27. Incidence of polycythemia vera in a defined population.
    Berglund S; Zettervall O
    Eur J Haematol; 1992 Jan; 48(1):20-6. PubMed ID: 1730276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
    Vannucchi AM; Masala G; Antonioli E; Chiara Susini M; Guglielmelli P; Pieri L; Maggi L; Caini S; Palli D; Bogani C; Ponziani V; Pancrazzi A; Annunziato F; Bosi A
    Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2068-73. PubMed ID: 19531676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway.
    Roaldsnes C; Holst R; Frederiksen H; Ghanima W
    Eur J Haematol; 2017 Jan; 98(1):85-93. PubMed ID: 27500783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of polycythemia vera and essential thrombocythemia.
    Ma X; Vanasse G; Cartmel B; Wang Y; Selinger HA
    Am J Hematol; 2008 May; 83(5):359-62. PubMed ID: 18181200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thrombopoietin receptor (Mpl) expression by megakaryocytes in myeloproliferative disorders.
    Bock O; Schlué J; Mengel M; Büsche G; Serinsöz E; Kreipe H
    J Pathol; 2004 May; 203(1):609-15. PubMed ID: 15095485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Myeloproliferative syndrome, myelofibrosis and erythrocytosis. A retrospective study].
    Retief FP; Du P Heyns A
    S Afr Med J; 1974 Dec; 48(59):2429-35. PubMed ID: 4532812
    [No Abstract]   [Full Text] [Related]  

  • 33. Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations.
    Bousquet M; Le Guellec S; Quelen C; Rigal-Huguet F; Delsol G; Brousset P
    Hum Pathol; 2006 Nov; 37(11):1458-64. PubMed ID: 16949922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
    Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders.
    Gupta R; Perumandla S; Patsiornik Y; Niranjan S; Ohri A
    J Natl Med Assoc; 2006 Nov; 98(11):1779-82. PubMed ID: 17128687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Occurrence of myelofibrosis in individual types of chronic myeloproliferative diseases].
    Adamkov M; Plank L; Szépe P
    Bratisl Lek Listy; 1998 May; 99(5):240-4. PubMed ID: 9673037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study.
    Frederiksen H; Farkas DK; Christiansen CF; Hasselbalch HC; Sørensen HT
    Blood; 2011 Dec; 118(25):6515-20. PubMed ID: 22039256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors.
    Cerquozzi S; Tefferi A
    Blood Cancer J; 2015 Nov; 5(11):e366. PubMed ID: 26565403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
    J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clonality in chronic myeloproliferative disorders defined by X-chromosome linked probes: demonstration of heterogeneity in lineage involvement.
    Tsukamoto N; Morita K; Maehara T; Okamoto K; Sakai H; Karasawa M; Naruse T; Omine M
    Br J Haematol; 1994 Feb; 86(2):253-8. PubMed ID: 7911034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.